660 related articles for article (PubMed ID: 33455920)
21. The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study.
Sozeri B; Ulu K; Kaya-Akça U; Haslak F; Pac-Kisaarslan A; Otar-Yener G; Baba O; Altug-Gucenmez O; Sahin N; Bağlan E; Sönmez HE; Cakmak F; Ozturk K; Gezgin-Yıldırım D; Şener S; Barut K; Batu ED; Yıldız M; Basaran O; Adrovic A; Sahin S; Ozdel S; Bilginer Y; Poyrazoglu MH; Demir F; Yuksel S; Kalyoncu M; Kasapcopur O; Ozen S; Aktay-Ayaz N
Rheumatol Int; 2022 Mar; 42(3):469-475. PubMed ID: 34570263
[TBL] [Abstract][Full Text] [Related]
22. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations.
Kroon FPB; Najm A; Alunno A; Schoones JW; Landewé RBM; Machado PM; Navarro-Compán V
Ann Rheum Dis; 2022 Mar; 81(3):422-432. PubMed ID: 34876462
[TBL] [Abstract][Full Text] [Related]
23. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.
Welzel T; Winskill C; Zhang N; Woerner A; Pfister M
Pediatr Rheumatol Online J; 2021 Mar; 19(1):46. PubMed ID: 33766063
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs.
Moradi S; Masoumi M; Mohammadi S; Vafaeimanesh J; Mohseni M; Mahdavi H; Aryannejad A
Intern Emerg Med; 2021 Jun; 16(4):919-923. PubMed ID: 33128696
[TBL] [Abstract][Full Text] [Related]
25. Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy.
Spila Alegiani S; Crisafulli S; Giorgi Rossi P; Mancuso P; Salvarani C; Atzeni F; Gini R; Kirchmayer U; Belleudi V; Kurotschka PK; Leoni O; Ludergnani M; Ferroni E; Baracco S; Massari M; Trifirò G;
Rheumatology (Oxford); 2021 Oct; 60(SI):SI25-SI36. PubMed ID: 33856453
[TBL] [Abstract][Full Text] [Related]
26. Severe COVID-19 in patients with immune-mediated rheumatic diseases: A stratified analysis from the SORCOM multicentre registry.
Boteanu A; Leon L; Pérez Esteban S; Rabadán Rubio E; Pavía Pascual M; Bonilla G; Bonilla González-Laganá C; García Fernandez A; Recuero Diaz S; Ruiz Gutierrez L; Sanmartín Martínez JJ; de la Torre-Rubio N; Nuño L; Sánchez Pernaute O; Del Bosque I; Lojo Oliveira L; Rodríguez Heredia JM; Clemente D; Abasolo L; Bachiller-Corral J
Mod Rheumatol; 2023 Dec; 34(1):97-105. PubMed ID: 36516217
[TBL] [Abstract][Full Text] [Related]
27. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.
Azmy V; Kaman K; Tang D; Zhao H; Dela Cruz C; Topal JE; Malinis M; Price CC
J Clin Immunol; 2021 May; 41(4):738-747. PubMed ID: 33459964
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes of Covid-19 in patients with rheumatic diseases and the effects of the pandemic on rheumatology outpatient care: A single-centre experience from Turkey.
Batıbay S; Koçak Ulucaköy R; Özdemir B; Günendi Z; Göğüş FN
Int J Clin Pract; 2021 Sep; 75(9):e14442. PubMed ID: 34105856
[TBL] [Abstract][Full Text] [Related]
30. Incidence of infection other than tuberculosis in patients with autoimmune rheumatic diseases treated with bDMARDs: a real-time clinical experience from India.
Chandrashekara S; Shobha V; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
Rheumatol Int; 2019 Mar; 39(3):497-507. PubMed ID: 30684040
[TBL] [Abstract][Full Text] [Related]
31. Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience.
Migkos MP; Kaltsonoudis E; Pelechas E; Drossou V; Karagianni PG; Kavvadias A; Voulgari PV; Drosos AA
Rheumatol Int; 2021 May; 41(5):903-909. PubMed ID: 33655421
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy.
Quartuccio L; Valent F; Pasut E; Tascini C; De Vita S
Joint Bone Spine; 2020 Oct; 87(5):439-443. PubMed ID: 32445935
[TBL] [Abstract][Full Text] [Related]
33. The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA).
Frodlund M; Nived P; Chatzidionysiou K; Södergren A; Klingberg E; Hansson M; Ohlsson S; Pin E; Bengtsson A; Klareskog L; Kapetanovic M
Microbiol Spectr; 2024 Apr; 12(4):e0298123. PubMed ID: 38441463
[TBL] [Abstract][Full Text] [Related]
34. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.
Iglesias-Julián E; López-Veloso M; de-la-Torre-Ferrera N; Barraza-Vengoechea JC; Delgado-López PD; Colazo-Burlato M; Ubeira-Iglesias M; Montero-Baladía M; Lorenzo-Martín A; Minguito-de-la-Iglesia J; García-Muñoz JP; Sanllorente-Sebastián R; Vicente-González B; Alemán-Alemán A; Buzón-Martín L
J Autoimmun; 2020 Dec; 115():102537. PubMed ID: 32843231
[TBL] [Abstract][Full Text] [Related]
35. Clinical features of patients with rheumatic and musculoskeletal diseases during the coronavirus disease 2019 pandemic and the association of its relapse with infection: Across-sectional study.
Zhang Y; Xu P; Huang J; Hu Z
Int J Rheum Dis; 2024 Apr; 27(4):e15150. PubMed ID: 38661306
[TBL] [Abstract][Full Text] [Related]
36. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
37. COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review.
Bakasis AD; Mavragani CP; Boki KA; Tzioufas AG; Vlachoyiannopoulos PG; Stergiou IE; Skopouli FN; Moutsopoulos HM
J Autoimmun; 2021 Sep; 123():102687. PubMed ID: 34311142
[TBL] [Abstract][Full Text] [Related]
38. COVID-19 in French patients with chronic inflammatory rheumatic diseases: Clinical features, risk factors and treatment adherence.
Costantino F; Bahier L; Tarancón LC; Leboime A; Vidal F; Bessalah L; Breban M; D'Agostino MA
Joint Bone Spine; 2021 Jan; 88(1):105095. PubMed ID: 33152484
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics of COVID-19 patients with underlying rheumatic diseases in Japan: data from a multicenter observational study using the COVID-19 Global Rheumatology Alliance physician-reported registry.
Kihara M; Sugihara T; Asano J; Sato M; Kaneko H; Muraoka S; Ohshima S; Nanki T
Clin Rheumatol; 2022 Dec; 41(12):3661-3673. PubMed ID: 35974224
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.
Pablos JL; Abasolo L; Alvaro-Gracia JM; Blanco FJ; Blanco R; Castrejón I; Fernandez-Fernandez D; Fernandez-Gutierrez B; Galindo-Izquierdo M; Gonzalez-Gay MA; Manrique-Arija S; Mena Vázquez N; Mera Varela A; Retuerto M; Seijas-Lopez A;
Ann Rheum Dis; 2020 Sep; 79(9):1170-1173. PubMed ID: 32532753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
